Medicamen Biotech logo

Medicamen Biotech

MEDICAMEQ NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹404 Cr
Volatility
High Risk
P/E Ratio
40.43
EBITDA
₹19.59 Cr
Return on Equity
3.08%
Debt to Equity
0.17
Book Value
₹203.17
EPS
₹5.81
52W High
₹447.65
52W Low
₹212.4

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • The company has delivered a poor sales growth of 11.9% over past five years.
  • Company has a low return on equity of 4.23% over last 3 years.
  • Dividend payout has been low at 14.5% of profits over last 3 years
  • Company has high debtors of 151 days.

Growth Rate

Revenue Growth
17.16% higher than 3Y
Net Income Growth
42.88% higher than 3Y
Cash Flow Change
-21.07% higher than 3Y
ROE
-32.9% lower than 3Y
ROCE
-28.49% higher than 3Y
EBITDA Margin (Avg.)
-18.14% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
41.94
43.54
46.5
47.32
43.05
44.74
45.14
29.61
43.04
47.17
46.91
60.65
47.9
Expenses
34.99
38.89
41.6
41.57
39.6
39.43
38.43
31.22
38.43
42.01
42.53
55.22
43.57
Operating Profit
6.95
4.65
4.9
5.75
3.45
5.31
6.71
-1.61
4.61
5.16
4.38
5.43
4.33
OPM %
16.57%
10.68%
10.54%
12.15%
8.01%
11.87%
14.86%
-5.44%
10.71%
10.94%
9.34%
8.95%
9.04%
Other Income
0.38
0.55
0.83
0.57
0.59
0.29
0.14
5.23
0.47
0.37
0.53
1.74
0.86
Interest
0.96
0.91
0.65
1.89
0.71
1.04
0.76
0.65
1.15
0.99
0.97
0.38
0.83
Depreciation
1.69
1.82
1.8
1.77
1.77
2.61
2.21
0.48
1.8
1.86
1.83
1.73
1.79
PBT
4.68
2.47
3.28
2.66
1.56
1.95
3.88
2.49
2.13
2.68
2.11
5.06
2.57
Tax %
15.81%
39.68%
38.11%
22.93%
48.72%
53.85%
24.74%
25.3%
24.88%
21.27%
22.27%
12.06%
28.4%
Net Profit
3.95
1.47
2.03
2.04
0.8
0.91
2.92
1.87
1.6
2.12
1.64
4.45
1.85
EPS in Rs
3.3
1.19
1.9
1.68
1.06
1.15
2.73
1.9
1.59
1.97
1.61
2.85
1.56
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
123
125
113
115
141
179
163
198
203
Expenses
105
106
93
91
117
156
148
178
183
Operating Profit
17
20
20
24
24
24
14
20
19
OPM %
14%
16%
17%
21%
17%
13%
9%
10%
10%
Other Income
4
2
1
2
2
2
6
3
4
Interest
1
1
2
2
3
6
4
4
3
Depreciation
2
2
3
6
6
7
7
7
7
PBT
18
18
16
18
17
13
10
12
12
Tax %
31%
26%
26%
18%
14%
27%
34%
18%
—
Net Profit
12
13
12
15
15
9
7
10
10
EPS in Rs
10.28
10.88
9.93
12.2
11.73
8.6
5.59
7.11
7.99
Div. Payout %
10%
5%
10%
8%
9%
12%
18%
14%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
12
12
12
12
13
13
13
14
Reserves
75
109
121
134
181
194
200
262
Borrowings
12
11
19
26
26
31
34
48
Other Liabilities
38
49
42
53
59
56
50
49
Total Liabilities
137
181
194
226
279
295
297
372
Fixed Assets
24
34
90
92
93
92
87
85
CWIP
15
40
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
Other Assets
97
107
104
133
186
203
210
287
Total Assets
137
181
194
226
279
295
297
372
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
13
13
4
-6
-7
-8
-33
Investing
-15
-37
-18
-8
-6
-6
-1
-3
Financing
-4
19
6
4
29
6
-1
64
Net Cash Flow
-14
-5
1
0
17
-6
-11
28
Free Cash Flow
-11
-25
-5
-4
-13
-13
-10
-38
CFO/OP
48
88
88
30
-13
-16
-47
-159
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
129
145
170
200
169
112
155
151
Inventory Days
67
78
27
188
228
234
268
251
Days Payable
134
173
169
302
241
154
184
144
Cash Conversion Cycle
62
51
28
86
156
193
239
259
Working Capital Days
116
130
126
147
156
123
186
193
ROCE %
—
16%
13%
12%
10%
8%
6%
5%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Medicamen Biotech insights

69 extracted metrics + investor summaries across FY10–FY26.

Log in — free

Shareholding Pattern

FIIs0.07%Govt.0.05%Promot.40.46%DIIs0.40%Others26.91%Public32.10%As ofJun 2026

Documents

1
Concall - Nov 2024 Nov 2024
2
Concall - Nov 2024 Nov 2024
3
Concall - Dec 2021 Dec 2021
4
Concall - Dec 2021 Dec 2021
5
Concall - Nov 2020 Nov 2020

Frequently Asked Questions about Medicamen Biotech

What does Medicamen Biotech Ltd do?
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
Where is Medicamen Biotech Ltd (MEDICAMEQ) listed?
Medicamen Biotech Ltd trades as MEDICAMEQ on the NSE and under code 531146 on the BSE.
Which sector does Medicamen Biotech Ltd belong to?
Medicamen Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a market capitalisation of ₹404.17 Cr, which places it in the Small Cap band.
What is the PE ratio of Medicamen Biotech Ltd?
Medicamen Biotech Ltd trades at a PE ratio of 40.43, on earnings per share of ₹5.81, against a book value of ₹203.17 per share.
What is the 52-week high and low of Medicamen Biotech Ltd?
Over the last 52 weeks Medicamen Biotech Ltd has traded between ₹212.4 and ₹447.65.
Does Medicamen Biotech Ltd pay dividends?
Medicamen Biotech Ltd has a dividend yield of 0.33%.
What is the Return on Equity (ROE) of Medicamen Biotech Ltd?
Medicamen Biotech Ltd reported a return on equity of 3.08%. Its debt-to-equity ratio is 0.17.

Company Information

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]

Website medicamen.com
CEO Mr. Rajesh Madan B. Pharma
Employees 376
Listed 2005-01-12
Face Value ₹ 10
Issued Size 1,35,62,815

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDICAMEQ.md for Medicamen Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List